Welcome to our dedicated page for Qiagen SEC filings (Ticker: QGEN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The QIAGEN N.V. (QGEN) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a foreign private issuer. QIAGEN files reports on Form 6-K and related documents under the Securities Exchange Act of 1934, covering quarterly financial information, press releases and other material updates for investors in its common shares.
Among the filings available are Form 6-K submissions that furnish QIAGEN’s U.S. GAAP quarterly reports, including periods ended June 30 and September 30, as well as press releases on topics such as unaudited financial results, synthetic share repurchase plans, acquisitions like Parse Biosciences, and leadership changes. These filings often include explanations of how QIAGEN uses adjusted (non-GAAP) metrics and constant currency measures alongside GAAP results, giving readers insight into how management evaluates business performance.
Investors can also review a Form 25 notification of removal from listing and/or registration filed by the New York Stock Exchange in January 2026 for QIAGEN N.V. common shares under Section 12(b) of the Exchange Act. This document confirms that the exchange has taken steps to strike the class of securities from listing and/or withdraw registration on that market, an important reference for understanding QGEN’s trading status on the NYSE.
Stock Titan enhances these filings with AI-powered summaries that explain the key points of lengthy documents such as quarterly reports or complex transaction announcements. Users can quickly see what QIAGEN reports about its Sample to Insight business, including segment performance, capital allocation actions like synthetic share repurchases, and updates on non-GAAP measures, while still having direct access to the original SEC documents.
In addition, this page helps track ongoing disclosure practices, such as corrections to prior balance sheet classifications described in certain Form 6-K filings, and the incorporation by reference of detailed exhibits like U.S. GAAP quarterly reports and major press releases. For anyone analyzing QGEN, this centralized view of SEC filings, combined with AI-generated highlights, offers a practical way to follow the company’s regulatory and financial reporting history.
Wellington Management Group and affiliates report a 6.5% beneficial ownership stake in Qiagen N.V. common stock on Schedule 13G/A (Amendment No. 3). The group reports beneficial ownership of 14,137,799 shares as of the event date, with all voting and dispositive power held on a shared basis.
Within the complex, Wellington Management Company LLP reports shared voting power over 12,155,318 shares and shared dispositive power over 12,416,628 shares, representing 5.7% of the class. The filing states that the securities are owned of record by clients of Wellington investment advisers and are held in the ordinary course of business, without the purpose or effect of changing or influencing control of Qiagen.
BlackRock, Inc. reports owning 20,678,987 shares of QIAGEN N.V. common stock, representing 10.0% of the class as of January 31, 2026. BlackRock has sole voting power over 19,575,569 shares and sole dispositive power over the full 20,678,987 shares.
The filing states that the securities are held in the ordinary course of business and not for the purpose of changing or influencing control of QIAGEN. Various underlying clients have rights to dividends or sale proceeds, but no single client holds more than five percent of the outstanding common shares.
QIAGEN N.V. reported Q4 2025 and full-year 2025 results that modestly exceeded its own outlook and set guidance for 2026. Q4 net sales were $540 million, up 4% (1% at constant exchange rates), with adjusted diluted EPS of $0.62, ahead of guidance of about $0.60 CER.
For 2025, net sales reached $2.09 billion, up 6% (5% CER), at the high end of its 4–5% CER growth outlook. Adjusted diluted EPS was $2.40 CER, above the about $2.38 CER target, and the adjusted operating margin improved to 29.5% despite tariff and currency headwinds.
The company’s growth pillars generated $1.49 billion CER in 2025 sales with 8% CER growth, and it returned more than $1.1 billion to shareholders via synthetic share repurchases and a new cash dividend. For 2026, QIAGEN targets at least 5% CER sales growth, about $1.64 billion CER from growth pillars and adjusted diluted EPS of at least $2.50 CER.
QIAGEN N.V. is having its common shares removed from listing and registration on the New York Stock Exchange. The filing states that the Exchange has followed its own rules to strike this class of securities, and that the company has followed Exchange procedures and regulatory requirements for a voluntary withdrawal from listing and registration. This means QIAGEN’s common shares will no longer trade on the NYSE once the delisting process is effective, and trading would need to occur on other markets or venues if available.
QIAGEN N.V. submitted a Form 6-K noting that it has issued a press release with details on completing a synthetic share repurchase plan. This plan combines a direct capital repayment to shareholders with a reverse stock split, which together are intended to adjust the company’s share structure while returning capital.
The press release, dated December 18, 2025, is included as Exhibit 99.1 and is incorporated by reference, meaning the detailed terms of the synthetic share repurchase and reverse stock split are provided in that accompanying document.
Wellington Management Group LLP filed an amended Schedule 13G reporting beneficial ownership in QIAGEN N.V. (QGEN) as of 09/30/2025. The filing lists 23,330,248 shares beneficially owned, representing 10.7% of the common stock.
The group reports 0 shares with sole voting or dispositive power, 19,132,735 with shared voting power, and 23,330,248 with shared dispositive power. One affiliated adviser, Wellington Management Company LLP, reports 6.9%. The securities are held for clients of Wellington-affiliated advisers, and the certification states they were acquired and are held in the ordinary course and not to change or influence control.
QIAGEN N.V. filed a Form 6-K summarizing several developments and furnishing related press releases as exhibits. The company announced a definitive agreement to fully acquire Parse Biosciences, a plan to return up to approximately $500 million to shareholders through a synthetic share repurchase, and that Thierry Bernard will step down as Chief Executive Officer and Managing Director.
QIAGEN also furnished a press release with unaudited financial results for the third quarter ended September 30, 2025. The filing reiterates the company’s use of non-GAAP and constant currency measures alongside GAAP results, noting reconciliations accompany the press release and that forward-looking non-GAAP reconciliations are not provided due to variability.
QIAGEN N.V. filed a Form 6-K as a foreign private issuer to provide its U.S. GAAP quarterly report for the three and six months ended June 30, 2025.
The quarterly report is furnished as Exhibit 99.1 and is incorporated by reference. The filing is signed on behalf of the company by Chief Financial Officer Roland Sackers.
Form 144 filed for QGEN reports a proposed sale of 25,000 common shares on the New York Stock Exchange with an aggregate market value of $1,220,000 and approximately 216,834,000 shares outstanding. The securities to be sold were acquired as restricted stock unit (RSU) awards on multiple dates in 2021 and 2022, with individual lots of 5,918; 5,247; 5,089; 4,253; and 4,493 shares. The filer states no securities were sold in the past three months and affirms they are not aware of undisclosed material adverse information about the issuer. The planned transaction is scheduled for approximately 08/15/2025.